Market LIVE
Published markets; coverage varies by country
Product profile · United States

XELJANZ

 ·  Patent Litigation & Settlement History ↓

IngredientTOFACITINIB CITRATE
Application typeNDA
Application213082
Product001
Dosage formSOLUTION
RouteORAL
StrengthEQ 1MG BASE/ML
Approval date2020-09-25
Marketing statusPrescription
Status event—
ApplicantPFIZER
Product source

Current GenericRadar decision

Year2023
SelectionEXISTING_GENERIC
ReviewDISQUALIFIED
Anchor typeFINAL_ANDA
Anchor date2023-09-25
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2023-09-25
Status event—

Exact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
RE417832025-12-08DS ————
———
RE417832026-06-08— ————
—2026-06-08—

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
M-14—2028-02-21————Source
PED—2028-08-21————Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
216878 / 001FINAL_APPROVAL · FINAL_APPROVED2023-09-25—HIKMA PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
217298 / 001FINAL_APPROVAL · FINAL_APPROVED2026-06-03—MSN LABORATORIES PRIVATE LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
218407 / 001FINAL_APPROVAL · FINAL_APPROVED2026-06-03—SUN PHARMACEUTICAL INDUSTRIES INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
218900 / 001FINAL_APPROVAL · FINAL_APPROVED2026-06-09—SAPTALIS PHARMACEUTICALS LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
219370 / 001FINAL_APPROVAL · FINAL_APPROVED2026-06-09—PHARMACO LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 5 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
216878 / 001HIKMA PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2023-09-25 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
217298 / 001MSN LABORATORIES PRIVATE LTDFINAL_APPROVAL · FINAL_APPROVED2026-06-03 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
218407 / 001SUN PHARMACEUTICAL INDUSTRIES INCFINAL_APPROVAL · FINAL_APPROVED2026-06-03 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
218900 / 001SAPTALIS PHARMACEUTICALS LLCFINAL_APPROVAL · FINAL_APPROVED2026-06-09 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
219370 / 001PHARMACO LLCFINAL_APPROVAL · FINAL_APPROVED2026-06-09 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
GENERIC2023-09-25TERMINAL_GENERIC_BASISExact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.